Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is overpriced on P/FCF.
Target Price
The average target price of NANO.PA is 20 and suggests 15% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell